![Awen Gallimore](https://profiles-cardiff.imgix.net/attachments/2436?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Yr Athro Awen Gallimore
- Siarad Cymraeg
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Awen Gallimore
Cyd-gyfarwyddwr Sefydliad Ymchwil Imiwnedd Systemau
Trosolwg
My laboratory is focussed on understanding how the immune system works. We are specifically interested in identifying the correlates of anti-viral and anti-cancer immunity and in using this information to guide the design of new treatments.
I run my lab with Professor Andrew Godkin, clinical academic and College Theme Lead for Immunology.
Detailed information relating to our cancer research can be found by visiting https://www.cancerimmunology.co.uk/
Response to the COVID-19 Pandemic
As an Immunology lab, we have responded to the pandemic by establishing a School-wide COVID-19 literature review to support clinicians and scientists working on COVID-19.
In addition, we are part of a UKRI-funded national consortium of immunologists examining the interplay between SARS-CoV-2 and the immune system. We are also part of a National Core Study to examine anti-viral T cell responses in asymptomatic SARS-CoV-2 infected individuals.
Cyhoeddiad
2026
- Marsden, M. et al. 2026. Cytomegalovirus-induced T cell responses accelerate Alzheimer’s disease progression in mice. Brain 149 (9), pp.3214-3227. awag043. (10.1093/brain/awag043)
- Lauder, S. N. et al. 2026. Optimising anti-PI3Kd and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple negative breast cancer improves outcome by removing treatment-related adverse events. Journal for ImmunoTherapy of Cancer 14 (2) e012157. (10.1136/jitc-2025-012157)
2025
- Oliver, J. et al. 2025. Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients. Cancer Immunology, Immunotherapy 75 (1) 3. (10.1007/s00262-025-04218-6)
- Burnell, S. E. A. et al. 2025. OSCAR is an online ML-powered tool for organoid cell counting using bright-field images. Cell Reports: Methods 5 (12) 101251. (10.1016/j.crmeth.2025.101251)
- Alamir, H. et al., 2025. TIM3 is a context-dependent coregulator of cytotoxic T cell function. Science Signaling 18 (905) eadk4594. (10.1126/scisignal.adk4594)
- Smith, K. A. et al. 2025. Helminth-induced prostaglandin signalling and dietary shifts in PUFA metabolism promote colitis-associated cancer. Journal of Lipid Research 66 (7) 100837. (10.1016/j.jlr.2025.100837)
2024
- Padilha, A. et al. 2024. Regulatory T cells play a role in determining the tumourigenicity of the Intestinal Stem Cell Niche. Gastro Hep Advances 4 (2) 100559. (10.1016/j.gastha.2024.09.014)
- Hopkins, G. et al., 2024. Lower humoral and cellular immunity following asymptomatic SARS-CoV-2 infection compared to symptomatic infection in education (the ACE cohort). Journal of Clinical Immunology 44 (6) 147. (10.1007/s10875-024-01739-0)
- Hulin-Curtis, S. et al., 2024. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Reports 43 (6) 114259. (10.1016/j.celrep.2024.114259)
2023
- Gallimore, A. and Tournier, C. 2023. Immuno-oncology. Essays in Biochemistry 67 (6), pp.903. (10.1042/EBC20230071)
- Chen, Y. et al. 2023. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Reports 42 (8) 112827. (10.1016/j.celrep.2023.112827)
- Milutinovic, S. and Gallimore, A. 2023. The link between T cell activation and development of functionally useful tumour-associated high endothelial venules. Discovery Immunology 2 (1) kyad006. (10.1093/discim/kyad006)
2022
- Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2 (12), pp.1641-1656. (10.1158/2767-9764.CRC-21-0123)
- Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127 , pp.1595–1602. (10.1038/s41416-022-01917-0)
- Scurr, M. J. et al. 2022. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications 13 5422. (10.1038/s41467-022-32985-8)
- Gallimore, A. 2022. Tumor-associated high endothelial venules: inroads enabling immune control of cancer progression. Cancer Immunology Research 10 (4) 371. (10.1158/2326-6066.CIR-22-0112)
- Pires, A. , Burnell, S. and Gallimore, A. 2022. Exploiting ECM remodelling to promote immune-mediated tumour destruction. Current Opinion in Immunology 74 , pp.32-38. (10.1016/j.coi.2021.09.006)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
2021
- Burnell, S. E. A. et al. 2021. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances 2 (1) ltab025. (10.1093/immadv/ltab025)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163 (4), pp.389-398. (10.1111/imm.13323)
- Lauder, S. N. , Vanhaesebroeck, B. and Gallimore, A. 2021. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach. British Journal of Cancer 125 , pp.467-469. (10.1038/s41416-021-01285-1)
- Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124 , pp.1552-1555. (10.1038/s41416-021-01283-3)
- Milutinovic, S. et al. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7 (3), pp.214-225. (10.1016/j.trecan.2020.10.001)
- MacLachlan, B. J. et al. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51 (2), pp.331-341. (10.1002/eji.202048753)
- Codd, A. S. et al. 2021. Neutrophilia, lymphopenia and myeloid dysfunction: A living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology 2 (1) iqab016. (10.1093/oxfimm/iqab016)
- Hanna, S. J. et al. 2021. T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology 2 (1)(10.1093/oxfimm/iqaa007)
- Lauder, S. N. et al. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology. Vol. 163, Elsevier. , pp.59-75. (10.1016/bs.mcb.2020.09.007)
2020
- Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8 (12), pp.1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
- Hughes, E. et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69 , pp.2063 - 2073. (10.1007/s00262-020-02603-x)
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8 (2) e000693. (10.1136/jitc-2020-000693)
- Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32 (2) 107885. (10.1016/j.celrep.2020.107885)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
2019
- MacLachlan, B. J. et al., 2019. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry 294 (52), pp.20246-20258. (10.1074/jbc.RA119.009437)
- Appanna, G. D. et al. 2019. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM: An International Journal of Medicine 112 (10), pp.793-795. (10.1093/qjmed/hcz161)
- Gallimore, A. , Quezada, S. A. and Roychoudhuri, R. 2019. Regulatory T cells in cancer: where are we now?. Immunology 157 (3), pp.187-189. (10.1111/imm.13088)
- Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19 98. (10.1186/s12876-019-1002-4)
- Watson, H. A. et al. 2019. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Frontiers in Immunology 10 1321. (10.3389/fimmu.2019.01321)
- Besneux, M. et al., 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68 , pp.247-256. (10.1007/s00262-018-2266-1)
2018
- Jones, E. , Gallimore, A. and Ager, A. 2018. Defining high endothelial venules and tertiary lymphoid structures in cancer. In: Tertiary Lymphoid Structures. Methods in Molecular Biology. Vol. 1845, Methods in Molecular Biology Humana Press. , pp.99-118. (10.1007/978-1-4939-8709-2_7)
- May, S. et al. 2018. Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. Journal of Pathology 245 (3), pp.270-282. (10.1002/path.5074)
- Hill, D. et al. 2018. Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. International Journal of Cancer 143 (1), pp.167-178. (10.1002/ijc.31298)
- Hughes, E. et al. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154 (1), pp.62-68. (10.1111/imm.12913)
- Miles, J. J. et al. 2018. Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation 128 (4), pp.1569-1580. (10.1172/JCI91512)
2017
- Colbeck, E. J. et al., 2017. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?. Frontiers in Immunology 8 1830. (10.3389/fimmu.2017.01830)
- Colbeck, E. J. et al., 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5 (11), pp.1005-1015. (10.1158/2326-6066.CIR-17-0131)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3 (10) e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Chen, H. et al., 2017. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells. Immunology and Cell Biology 95 (7), pp.620-629. (10.1038/icb.2017.21)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35 (7), pp.154-154. (10.1200/JCO.2017.35.7_suppl.154)
2016
- Hughes, E. et al., 2016. Treating metastatic disease through manipulation of regulatory T cells. European Journal of Immunology 46 , pp.578-578. 827. (10.1002/eji.201670200)
2015
- Colbeck, E. et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6 (28), pp.24649-24659. (10.18632/oncotarget.5584)
- Scurr, M. J. et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107 (4) djv001. (10.1093/jnci/djv001)
- Costa Bento, D. F. et al. 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4 (3), pp.653-660. e974374. (10.4161/2162402X.2014.974374)
- Ford, C. A. et al., 2015. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology 25 (5), pp.577-588. (10.1016/j.cub.2014.12.059)
- Stack, G. et al. 2015. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathogens 11 (2) e1004641. (10.1371/journal.ppat.1004641)
- Ondondo, B. et al., 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145 (1), pp.94-104. (10.1111/imm.12430)
- Pembroke, T. , Gallimore, A. M. and Godkin, A. J. 2015. Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods 424 , pp.131-135. (10.1016/j.jim.2015.04.011)
2014
- Stacey, M. A. et al. 2014. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. Cell Host and Microbe 15 (4), pp.471-483. (10.1016/j.chom.2014.03.003)
- Ondondo, B. et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134 (9), pp.2156-2167. (10.1002/ijc.28556)
2013
- Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
- Ondondo, B. et al., 2013. Home sweet home: The tumor microenvironment as a haven for regulatory T cells. Frontiers in Immunology 4 197. (10.3389/fimmu.2013.00197)
- Pembroke, T. , Gallimore, A. and Godkin, A. 2013. Flow cytometry makes all the difference. Journal of Hepatology 59 (4), pp.909-910. (10.1016/j.jhep.2013.05.047)
- Pembroke, T. et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
- Gallimore, A. M. and Godkin, A. J. 2013. Epithelial barriers, microbiota, and colorectal cancer. New England Journal of Medicine 368 (3), pp.282-284. (10.1056/NEJMcibr1212341)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43 (10), pp.2613-2625. (10.1002/eji.201243018)
- Pembroke, T. , Gallimore, A. and Godkin, A. 2013. Rapid innate control of antigen abrogates adaptive immunity. Immunology 138 (4), pp.293-297. (10.1111/imm.12048)
- Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1 (6) 416. (10.1158/2326-6066.CIR-13-0035)
2012
- Hindley, J. P. et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72 (21), pp.5473-5482. (10.1158/0008-5472.CAN-12-1912)
- Kempshall, E. et al. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunology and Cell Biology 90 (9), pp.869-871. (10.1038/icb.2012.30)
- Cole, D. et al. 2012. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications 3 665. (10.1038/ncomms1665)
- Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61 (8), pp.1163-1171. (10.1136/gutjnl-2011-300970)
- Humphreys, I. R. et al. 2012. Avidity of influenza-specific memory CD8+T-cell populations decays over time compromising antiviral immunity. European Journal of Immunology 42 (12), pp.3235-3242. (10.1002/eji.201242575)
- Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42 (9), pp.2383-2394. (10.1002/eji.201142072)
- Pembroke, T. et al. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61 (S2), pp.A144-A145. (10.1136/gutjnl-2012-302514b.174)
- Scurr, M. J. , Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61 (S2) A109. (10.1136/gutjnl-2012-302514b.88)
- Scurr, M. J. , Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279 (1), pp.21-24. (10.1016/j.cellimm.2012.08.004)
- Twohig, J. P. et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26 (8), pp.3575-3586. (10.1096/fj.11-200618)
2011
- Clement, M. et al. 2011. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. The Journal of Immunology 187 (2), pp.654-663. (10.4049/jimmunol.1003941)
- Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66 (5), pp.368-374. (10.1136/thx.2010.150318)
- Ruge, F. et al. 2011. Delineating immune-mediated mechanisms underlying hair follicle destruction in the mouse mutant defolliculated. Journal of Investigative Dermatology 131 (3), pp.572-579. (10.1038/jid.2010.379)
- Godkin, A. J. and Gallimore, A. M. 2011. Setting the threshold for extra-thymic differentiation of Foxp3+ Tregs: TGF-β-dependent and T-cell autonomous. European Journal of Immunology 41 (5), pp.1218-1220. (10.1002/eji.201141576)
- Hindley, J. P. et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research 71 (3), pp.736-746. (10.1158/0008-5472.CAN-10-1797)
2010
- Cuff, S. et al. 2010. Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells. The Journal of Immunology 184 (2), pp.607-614. (10.4049/jimmunol.0804089)
- Lauder, S. N. et al. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131 (S1), pp.186. (10.1111/j.1365-2567.2010.03390.x)
- Richards, H. C. et al. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131 (4), pp.583-592. (10.1111/j.1365-2567.2010.03333.x)
2009
- Gallagher, K. M. E. et al. 2009. Type I interferon (IFNα) acts directly on human memory CD4+ T cells altering their response to antigen. The Journal of Immunology 183 (5), pp.2915-2920. (10.4049/jimmunol.0801607)
- Baalasubramanian, S. et al. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182 (9), pp.5203-5207. (10.4049/jimmunol.0804243)
2008
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111 (10), pp.5187-5194. (10.1182/blood-2007-10-117283)
- Longhi, M. P. et al., 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4 (2) e1000006. (10.1371/journal.ppat.1000006)
- Richards, H. C. et al. 2008. CD62L (L-Selectin) down-regulation does not affect memory T cell distribution but failure to shed compromises anti-viral immunity. Journal of Immunology 180 (1), pp.198-206.
- Gallimore, A. M. and Simon, A. K. 2008. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27 (45), pp.5886-5893. (10.1038/onc.2008.269)
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125 (s1), pp.62-62. (10.1111/j.1365-2567.2008.02974.x)
2007
- Boulter, J. M. et al. 2007. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology 37 (3), pp.798-806. (10.1002/eji.200636743)
- Simon, A. K. et al., 2007. Regulatory T cells inhibit Fas ligand induced innate and adaptive tumour immunity. European Journal of Immunology 37 (3), pp.758-767. (10.1002/eji.200636593)
- Betts, G. et al., 2007. The impact of regulatory T cells on carcinogen-induced sarcogenesis. British Journal of Cancer 96 (12), pp.1849-1854. (10.1038/sj.bjc.6603824)
- Betts, G. J. , Godkin, A. J. and Gallimore, A. M. 2007. Reply: forkhead box P3-positive regulatory T cells in immune surveillance and cancer. British Journal of Cancer 97 , pp.1017-1018. (10.1038/sj.bjc.6603940)
- Gallimore, A. M. and Godkin, A. J. 2007. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123 (2), pp.157-163. (10.1111/j.1365-2567.2007.02748.x)
2006
- Betts, G. J. et al. 2006. Regulating the immune response to tumours. Advanced Drug Delivery Reviews 58 (8), pp.948-961. (10.1016/j.addr.2006.05.006)
- Wise, M. P. , Gallimore, A. M. and Godkin, A. J. 2006. T-Cell costimulation [Letter]. New England Journal of Medicine 355 (24), pp.2594-2595. (10.1056/NEJMc062767)
2005
- Longhi, M. P. et al., 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175 (11), pp.7098-7102.
- Clarke, S. L. et al., 2005. Analysis of CD4(+)CD25(hi) cells in peripheral blood and lymph nodes of patients with colorectal cancer. Immunology 116 (1), pp.37-37. (10.1111/j.1365-2567.2005.02287.x)
- Richards, H. E. et al., 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116 (s1), pp.36-36. (10.1111/j.1365-2567.2005.02287.x)
2003
- Jones, E. et al., 2003. The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology 109 (1), pp.68-75. (10.1046/j.1365-2567.2003.01636.x)
2002
- Simon, A. K. et al., 2002. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2 (4), pp.315-322. (10.1016/S1535-6108(02)00151-4)
- Golgher, D. et al., 2002. CD25+ regulatory cells uncover immune responses to shared tumour rejection antigens. European Journal of Immunology 32 (11), pp.3267-3275. (10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1)
1999
- Bachmann, M. F. et al., 1999. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. Journal of Experimental Medicine 189 (10), pp.1521-1530.
1998
- Gallimore, A. M. et al. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. Journal of Experimental Medicine 187 (10), pp.1647-1657.
- Gallimore, A. M. , Hengartner, H. and Zinkernagel, R. 1998. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunological Reviews 164 , pp.29-36. (10.1111/j.1600-065X.1998.tb01205.x)
- Gallimore, A. M. et al. 1998. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology 28 (10), pp.3301-3311.
- Gallimore, A. M. et al. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Molecular Immunology 35 (10), pp.581-591.
1996
- Gotch, F. , Gallimore, A. M. and McMichael, A. 1996. Cytotoxic T cells--protection from disease progression--protection from infection. Immunology Letters 51 (1-2), pp.125-128. (10.1016/0165-2478(96)02566-7)
1995
- Boyson, J. E. et al., 1995. The MHC E locus in macaques is polymorphic and is conserved between macaques and humans. Immunogenetics 41 (2-3), pp.59-68. (10.1007/BF00182314)
- Gallimore, A. M. et al. 1995. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Natural Medicines 1 (11), pp.1167-1173.
- Rowland-Jones, S. et al., 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Natural Medicines 1 (1), pp.59-64.
1993
- Gotch, F. et al., 1993. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. The Journal of Immunology 151 (6), pp.3361-3369.
Adrannau llyfrau
- Lauder, S. N. et al. 2021. Using methylcholanthrene-induced fibrosarcomas to study tumor immunology. In: Methods in Cell Biology. Vol. 163, Elsevier. , pp.59-75. (10.1016/bs.mcb.2020.09.007)
- Jones, E. , Gallimore, A. and Ager, A. 2018. Defining high endothelial venules and tertiary lymphoid structures in cancer. In: Tertiary Lymphoid Structures. Methods in Molecular Biology. Vol. 1845, Methods in Molecular Biology Humana Press. , pp.99-118. (10.1007/978-1-4939-8709-2_7)
Erthyglau
- Marsden, M. et al. 2026. Cytomegalovirus-induced T cell responses accelerate Alzheimer’s disease progression in mice. Brain 149 (9), pp.3214-3227. awag043. (10.1093/brain/awag043)
- Lauder, S. N. et al. 2026. Optimising anti-PI3Kd and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple negative breast cancer improves outcome by removing treatment-related adverse events. Journal for ImmunoTherapy of Cancer 14 (2) e012157. (10.1136/jitc-2025-012157)
- Oliver, J. et al. 2025. Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients. Cancer Immunology, Immunotherapy 75 (1) 3. (10.1007/s00262-025-04218-6)
- Burnell, S. E. A. et al. 2025. OSCAR is an online ML-powered tool for organoid cell counting using bright-field images. Cell Reports: Methods 5 (12) 101251. (10.1016/j.crmeth.2025.101251)
- Alamir, H. et al., 2025. TIM3 is a context-dependent coregulator of cytotoxic T cell function. Science Signaling 18 (905) eadk4594. (10.1126/scisignal.adk4594)
- Smith, K. A. et al. 2025. Helminth-induced prostaglandin signalling and dietary shifts in PUFA metabolism promote colitis-associated cancer. Journal of Lipid Research 66 (7) 100837. (10.1016/j.jlr.2025.100837)
- Padilha, A. et al. 2024. Regulatory T cells play a role in determining the tumourigenicity of the Intestinal Stem Cell Niche. Gastro Hep Advances 4 (2) 100559. (10.1016/j.gastha.2024.09.014)
- Hopkins, G. et al., 2024. Lower humoral and cellular immunity following asymptomatic SARS-CoV-2 infection compared to symptomatic infection in education (the ACE cohort). Journal of Clinical Immunology 44 (6) 147. (10.1007/s10875-024-01739-0)
- Hulin-Curtis, S. et al., 2024. A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation. Cell Reports 43 (6) 114259. (10.1016/j.celrep.2024.114259)
- Gallimore, A. and Tournier, C. 2023. Immuno-oncology. Essays in Biochemistry 67 (6), pp.903. (10.1042/EBC20230071)
- Chen, Y. et al. 2023. Structural definition of HLA class II-presented SARS-CoV-2 epitopes reveals a mechanism to escape pre-existing CD4+ T cell immunity. Cell Reports 42 (8) 112827. (10.1016/j.celrep.2023.112827)
- Milutinovic, S. and Gallimore, A. 2023. The link between T cell activation and development of functionally useful tumour-associated high endothelial venules. Discovery Immunology 2 (1) kyad006. (10.1093/discim/kyad006)
- Milutinovic, S. et al. 2022. Three-dimensional imaging reveals immune-driven tumor-associated high endothelial venules as a key correlate of tumor rejection following depletion of regulatory T cells. Cancer Research Communications 2 (12), pp.1641-1656. (10.1158/2767-9764.CRC-21-0123)
- Lauder, S. N. et al. 2022. Treg-driven tumour control by PI3Kδ inhibition limits myeloid-derived suppressor cell expansion. British Journal of Cancer 127 , pp.1595–1602. (10.1038/s41416-022-01917-0)
- Scurr, M. J. et al. 2022. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. Nature Communications 13 5422. (10.1038/s41467-022-32985-8)
- Gallimore, A. 2022. Tumor-associated high endothelial venules: inroads enabling immune control of cancer progression. Cancer Immunology Research 10 (4) 371. (10.1158/2326-6066.CIR-22-0112)
- Pires, A. , Burnell, S. and Gallimore, A. 2022. Exploiting ECM remodelling to promote immune-mediated tumour destruction. Current Opinion in Immunology 74 , pp.32-38. (10.1016/j.coi.2021.09.006)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165 (2), pp.250-259. (10.1111/imm.13433)
- Burnell, S. E. A. et al. 2021. Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity. Immunotherapy Advances 2 (1) ltab025. (10.1093/immadv/ltab025)
- Teijeira Crespo, A. et al. 2021. Pouring petrol on the flames: using oncolytic virotherapies to enhance tumour immunogenicity. Immunology 163 (4), pp.389-398. (10.1111/imm.13323)
- Lauder, S. N. , Vanhaesebroeck, B. and Gallimore, A. 2021. Sequential targeting of PI3Kδ and LAG3 as an effective anti-cancer approach. British Journal of Cancer 125 , pp.467-469. (10.1038/s41416-021-01285-1)
- Thomson, A. et al. 2021. Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells. British Journal of Cancer 124 , pp.1552-1555. (10.1038/s41416-021-01283-3)
- Milutinovic, S. et al. 2021. The dual role of high endothelial venules in cancer progression versus immunity. Trends in Cancer 7 (3), pp.214-225. (10.1016/j.trecan.2020.10.001)
- MacLachlan, B. J. et al. 2021. Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. European Journal of Immunology 51 (2), pp.331-341. (10.1002/eji.202048753)
- Codd, A. S. et al. 2021. Neutrophilia, lymphopenia and myeloid dysfunction: A living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology 2 (1) iqab016. (10.1093/oxfimm/iqab016)
- Hanna, S. J. et al. 2021. T cell phenotypes in COVID-19 - a living review. Oxford Open Immunology 2 (1)(10.1093/oxfimm/iqaa007)
- Pires, A. et al. 2020. Immune remodelling of the extracellular matrix drives loss of cancer stem cells and tumor rejection. Cancer Immunology Research 8 (12), pp.1520 - 1531. (10.1158/2326-6066.CIR-20-0070)
- Hughes, E. et al. 2020. Primary breast tumours but not lung metastases induce protective anti-tumour immune responses after Treg-depletion. Cancer Immunology, Immunotherapy 69 , pp.2063 - 2073. (10.1007/s00262-020-02603-x)
- Lauder, S. N. et al. 2020. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3. Journal for ImmunoTherapy of Cancer 8 (2) e000693. (10.1136/jitc-2020-000693)
- Greenshields-Watson, A. et al. 2020. CD4 + T cells recognize conserved influenza A epitopes through shared patterns of V-Gene usage and complementary biochemical features. Cell Reports 32 (2) 107885. (10.1016/j.celrep.2020.107885)
- Scurr, M. J. et al. 2020. Cancer antigen discovery is enabled by RNA-sequencing of highly purified malignant and non-malignant cells. Clinical Cancer Research (10.1158/1078-0432.CCR-19-3087)
- MacLachlan, B. J. et al., 2019. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope. Journal of Biological Chemistry 294 (52), pp.20246-20258. (10.1074/jbc.RA119.009437)
- Appanna, G. D. et al. 2019. Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome. QJM: An International Journal of Medicine 112 (10), pp.793-795. (10.1093/qjmed/hcz161)
- Gallimore, A. , Quezada, S. A. and Roychoudhuri, R. 2019. Regulatory T cells in cancer: where are we now?. Immunology 157 (3), pp.187-189. (10.1111/imm.13088)
- Thomson, A. et al. 2019. The Ussing chamber system for measuring intestinal permeability in health and disease. BMC Gastroenterology 19 98. (10.1186/s12876-019-1002-4)
- Watson, H. A. et al. 2019. L-selectin enhanced T cells improve the efficacy of cancer immunotherapy. Frontiers in Immunology 10 1321. (10.3389/fimmu.2019.01321)
- Besneux, M. et al., 2019. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design. Cancer Immunology, Immunotherapy 68 , pp.247-256. (10.1007/s00262-018-2266-1)
- May, S. et al. 2018. Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. Journal of Pathology 245 (3), pp.270-282. (10.1002/path.5074)
- Hill, D. et al. 2018. Hyperactive gp130/STAT3-driven gastric tumourigenesis promotes submucosal tertiary lymphoid structure development. International Journal of Cancer 143 (1), pp.167-178. (10.1002/ijc.31298)
- Hughes, E. et al. 2018. T‐cell modulation by cyclophosphamide for tumour therapy. Immunology 154 (1), pp.62-68. (10.1111/imm.12913)
- Miles, J. J. et al. 2018. Peptide mimic for influenza vaccination using nonnatural combinatorial chemistry. Journal of Clinical Investigation 128 (4), pp.1569-1580. (10.1172/JCI91512)
- Colbeck, E. J. et al., 2017. Tertiary lymphoid structures in cancer: drivers of antitumor immunity, immunosuppression, or bystander sentinels in disease?. Frontiers in Immunology 8 1830. (10.3389/fimmu.2017.01830)
- Colbeck, E. J. et al., 2017. Treg depletion licenses T cell-driven HEV neogenesis and promotes tumor destruction. Cancer Immunology Research 5 (11), pp.1005-1015. (10.1158/2326-6066.CIR-17-0131)
- Scurr, M. et al. 2017. Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial. JAMA Oncology 3 (10) e172579. (10.1001/jamaoncol.2017.2579)
- Scurr, M. J. et al. 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research clincanres.0895.2017. (10.1158/1078-0432.CCR-17-0895)
- Chen, H. et al., 2017. Synergistic targeting of breast cancer stem-like cells by human γδ T cells and CD8+ T cells. Immunology and Cell Biology 95 (7), pp.620-629. (10.1038/icb.2017.21)
- Scurr, M. et al. 2017. MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.. Journal of Clinical Oncology 35 (7), pp.154-154. (10.1200/JCO.2017.35.7_suppl.154)
- Hughes, E. et al., 2016. Treating metastatic disease through manipulation of regulatory T cells. European Journal of Immunology 46 , pp.578-578. 827. (10.1002/eji.201670200)
- Colbeck, E. et al. 2015. Eliminating roles for T-bet and IL-2 but revealing superior activation and proliferation as mechanisms underpinning dominance of regulatory T cells in tumors. Oncotarget 6 (28), pp.24649-24659. (10.18632/oncotarget.5584)
- Scurr, M. J. et al. 2015. Assessing the prognostic value of preoperative carcinoembryonic antigen-specific T-cell responses in colorectal cancer. JNCI: Journal of the National Cancer Institute 107 (4) djv001. (10.1093/jnci/djv001)
- Costa Bento, D. F. et al. 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4 (3), pp.653-660. e974374. (10.4161/2162402X.2014.974374)
- Ford, C. A. et al., 2015. Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology 25 (5), pp.577-588. (10.1016/j.cub.2014.12.059)
- Stack, G. et al. 2015. CD200 receptor restriction of myeloid cell responses antagonizes antiviral immunity and facilitates cytomegalovirus persistence within mucosal tissue. PLoS Pathogens 11 (2) e1004641. (10.1371/journal.ppat.1004641)
- Ondondo, B. et al., 2015. A distinct chemokine axis does not account for enrichment of Foxp3+ CD4+T cells in carcinogen-induced fibrosarcomas. Immunology 145 (1), pp.94-104. (10.1111/imm.12430)
- Pembroke, T. , Gallimore, A. M. and Godkin, A. J. 2015. Tracking the kinetics of intrahepatic immune responses by repeated fine needle aspiration of the liver. Journal of Immunological Methods 424 , pp.131-135. (10.1016/j.jim.2015.04.011)
- Stacey, M. A. et al. 2014. Neutrophils recruited by IL-22 in peripheral tissues function as TRAIL-dependent antiviral effectors against MCMV. Cell Host and Microbe 15 (4), pp.471-483. (10.1016/j.chom.2014.03.003)
- Ondondo, B. et al. 2014. Progression of carcinogen-induced fibrosarcomas is associated with the accumulation of naïve CD4+ T cellsviablood vessels and lymphatics. International Journal of Cancer 134 (9), pp.2156-2167. (10.1002/ijc.28556)
- Scurr, M. J. et al. 2013. Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3- T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells. Mucosal Immunology n/a (10.1038/mi.2013.62)
- Ondondo, B. et al., 2013. Home sweet home: The tumor microenvironment as a haven for regulatory T cells. Frontiers in Immunology 4 197. (10.3389/fimmu.2013.00197)
- Pembroke, T. , Gallimore, A. and Godkin, A. 2013. Flow cytometry makes all the difference. Journal of Hepatology 59 (4), pp.909-910. (10.1016/j.jhep.2013.05.047)
- Pembroke, T. et al. 2013. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in-vivo resistance to interferon treatment. Gut n/a (10.1136/gutjnl-2013-304472)
- Gallimore, A. M. and Godkin, A. J. 2013. Epithelial barriers, microbiota, and colorectal cancer. New England Journal of Medicine 368 (3), pp.282-284. (10.1056/NEJMcibr1212341)
- Lauder, S. N. et al. 2013. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. European Journal of Immunology 43 (10), pp.2613-2625. (10.1002/eji.201243018)
- Pembroke, T. , Gallimore, A. and Godkin, A. 2013. Rapid innate control of antigen abrogates adaptive immunity. Immunology 138 (4), pp.293-297. (10.1111/imm.12048)
- Scurr, M. et al. 2013. Escalating regulation of 5T4-specific IFN- + CD4+ T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy. Cancer Immunology Research 1 (6) 416. (10.1158/2326-6066.CIR-13-0035)
- Hindley, J. P. et al. 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T cell depletion. Cancer Research 72 (21), pp.5473-5482. (10.1158/0008-5472.CAN-12-1912)
- Kempshall, E. et al. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunology and Cell Biology 90 (9), pp.869-871. (10.1038/icb.2012.30)
- Cole, D. et al. 2012. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4+ T-cell repertoire selection. Nature Communications 3 665. (10.1038/ncomms1665)
- Betts, G. J. et al. 2012. Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer. Gut 61 (8), pp.1163-1171. (10.1136/gutjnl-2011-300970)
- Humphreys, I. R. et al. 2012. Avidity of influenza-specific memory CD8+T-cell populations decays over time compromising antiviral immunity. European Journal of Immunology 42 (12), pp.3235-3242. (10.1002/eji.201242575)
- Pembroke, T. et al. 2012. Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+T-cell immunity. European Journal of Immunology 42 (9), pp.2383-2394. (10.1002/eji.201142072)
- Pembroke, T. et al. 2012. PMO-174 Intrahepatic natural killer cell phenotyping and functional analysis by fine needle aspiration in chronic HCV infection. Gut 61 (S2), pp.A144-A145. (10.1136/gutjnl-2012-302514b.174)
- Scurr, M. J. , Gallimore, A. M. and Godkin, A. J. 2012. PMO-088 A large proportion of colorectal tumour-infiltrating CD4+ T cells are suppressive irrespective of FOXP3 expression. Gut 61 (S2) A109. (10.1136/gutjnl-2012-302514b.88)
- Scurr, M. J. , Gallimore, A. M. and Godkin, A. J. 2012. T cell subsets and colorectal cancer: discerning the good from the bad. Cellular Immunology 279 (1), pp.21-24. (10.1016/j.cellimm.2012.08.004)
- Twohig, J. P. et al. 2012. The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T-cell immunity. The FASEB Journal 26 (8), pp.3575-3586. (10.1096/fj.11-200618)
- Clement, M. et al. 2011. Anti-CD8 antibodies can trigger CD8+ T cell effector function in the absence of TCR engagement and improve peptide-MHCI tetramer staining. The Journal of Immunology 187 (2), pp.654-663. (10.4049/jimmunol.1003941)
- Lauder, S. N. et al. 2011. Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66 (5), pp.368-374. (10.1136/thx.2010.150318)
- Ruge, F. et al. 2011. Delineating immune-mediated mechanisms underlying hair follicle destruction in the mouse mutant defolliculated. Journal of Investigative Dermatology 131 (3), pp.572-579. (10.1038/jid.2010.379)
- Godkin, A. J. and Gallimore, A. M. 2011. Setting the threshold for extra-thymic differentiation of Foxp3+ Tregs: TGF-β-dependent and T-cell autonomous. European Journal of Immunology 41 (5), pp.1218-1220. (10.1002/eji.201141576)
- Hindley, J. P. et al. 2011. Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors. Cancer Research 71 (3), pp.736-746. (10.1158/0008-5472.CAN-10-1797)
- Cuff, S. et al. 2010. Antigen specificity determines the pro- or antitumoral nature of CD8+ T cells. The Journal of Immunology 184 (2), pp.607-614. (10.4049/jimmunol.0804089)
- Lauder, S. N. et al. 2010. A critical role for interleukin-6 in limiting influenza-induced pathology and generating heterosubtypic immunity [Abstract]. Immunology 131 (S1), pp.186. (10.1111/j.1365-2567.2010.03390.x)
- Richards, H. C. et al. 2010. Novel role of regulatory T cells in limiting early neutrophil responses in skin. Immunology 131 (4), pp.583-592. (10.1111/j.1365-2567.2010.03333.x)
- Gallagher, K. M. E. et al. 2009. Type I interferon (IFNα) acts directly on human memory CD4+ T cells altering their response to antigen. The Journal of Immunology 183 (5), pp.2915-2920. (10.4049/jimmunol.0801607)
- Baalasubramanian, S. et al. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182 (9), pp.5203-5207. (10.4049/jimmunol.0804243)
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111 (10), pp.5187-5194. (10.1182/blood-2007-10-117283)
- Longhi, M. P. et al., 2008. Interleukin-6 is crucial for recall of influenza-specific memory cd4+ t cells. PLoS Pathogens 4 (2) e1000006. (10.1371/journal.ppat.1000006)
- Richards, H. C. et al. 2008. CD62L (L-Selectin) down-regulation does not affect memory T cell distribution but failure to shed compromises anti-viral immunity. Journal of Immunology 180 (1), pp.198-206.
- Gallimore, A. M. and Simon, A. K. 2008. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene 27 (45), pp.5886-5893. (10.1038/onc.2008.269)
- Jones, G. W. et al. 2008. TL1A/TNFSF15 promotes a STAT1-mediated suppression of IL-17-secreting T-helper cells [Abstract]. Immunology 125 (s1), pp.62-62. (10.1111/j.1365-2567.2008.02974.x)
- Boulter, J. M. et al. 2007. Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. European Journal of Immunology 37 (3), pp.798-806. (10.1002/eji.200636743)
- Simon, A. K. et al., 2007. Regulatory T cells inhibit Fas ligand induced innate and adaptive tumour immunity. European Journal of Immunology 37 (3), pp.758-767. (10.1002/eji.200636593)
- Betts, G. et al., 2007. The impact of regulatory T cells on carcinogen-induced sarcogenesis. British Journal of Cancer 96 (12), pp.1849-1854. (10.1038/sj.bjc.6603824)
- Betts, G. J. , Godkin, A. J. and Gallimore, A. M. 2007. Reply: forkhead box P3-positive regulatory T cells in immune surveillance and cancer. British Journal of Cancer 97 , pp.1017-1018. (10.1038/sj.bjc.6603940)
- Gallimore, A. M. and Godkin, A. J. 2007. Regulatory T cells and tumour immunity - observations in mice and men. Immunology 123 (2), pp.157-163. (10.1111/j.1365-2567.2007.02748.x)
- Betts, G. J. et al. 2006. Regulating the immune response to tumours. Advanced Drug Delivery Reviews 58 (8), pp.948-961. (10.1016/j.addr.2006.05.006)
- Wise, M. P. , Gallimore, A. M. and Godkin, A. J. 2006. T-Cell costimulation [Letter]. New England Journal of Medicine 355 (24), pp.2594-2595. (10.1056/NEJMc062767)
- Longhi, M. P. et al., 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175 (11), pp.7098-7102.
- Clarke, S. L. et al., 2005. Analysis of CD4(+)CD25(hi) cells in peripheral blood and lymph nodes of patients with colorectal cancer. Immunology 116 (1), pp.37-37. (10.1111/j.1365-2567.2005.02287.x)
- Richards, H. E. et al., 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116 (s1), pp.36-36. (10.1111/j.1365-2567.2005.02287.x)
- Jones, E. et al., 2003. The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology 109 (1), pp.68-75. (10.1046/j.1365-2567.2003.01636.x)
- Simon, A. K. et al., 2002. Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell 2 (4), pp.315-322. (10.1016/S1535-6108(02)00151-4)
- Golgher, D. et al., 2002. CD25+ regulatory cells uncover immune responses to shared tumour rejection antigens. European Journal of Immunology 32 (11), pp.3267-3275. (10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1)
- Bachmann, M. F. et al., 1999. Developmental regulation of Lck targeting to the CD8 coreceptor controls signaling in naive and memory T cells. Journal of Experimental Medicine 189 (10), pp.1521-1530.
- Gallimore, A. M. et al. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. Journal of Experimental Medicine 187 (10), pp.1647-1657.
- Gallimore, A. M. , Hengartner, H. and Zinkernagel, R. 1998. Hierarchies of antigen-specific cytotoxic T-cell responses. Immunological Reviews 164 , pp.29-36. (10.1111/j.1600-065X.1998.tb01205.x)
- Gallimore, A. M. et al. 1998. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. European Journal of Immunology 28 (10), pp.3301-3311.
- Gallimore, A. M. et al. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Molecular Immunology 35 (10), pp.581-591.
- Gotch, F. , Gallimore, A. M. and McMichael, A. 1996. Cytotoxic T cells--protection from disease progression--protection from infection. Immunology Letters 51 (1-2), pp.125-128. (10.1016/0165-2478(96)02566-7)
- Boyson, J. E. et al., 1995. The MHC E locus in macaques is polymorphic and is conserved between macaques and humans. Immunogenetics 41 (2-3), pp.59-68. (10.1007/BF00182314)
- Gallimore, A. M. et al. 1995. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Natural Medicines 1 (11), pp.1167-1173.
- Rowland-Jones, S. et al., 1995. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Natural Medicines 1 (1), pp.59-64.
- Gotch, F. et al., 1993. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. The Journal of Immunology 151 (6), pp.3361-3369.
Ymchwil
Although the main job or our immune system is to protect us from infection by pathogens, it has recently it has become apparent that it is possible to persuade the immune system to recognise and kill cancer. In fact, new medicines have been made which boost the immune systems’ ability to recognise cancer. This type of treatment is called immunotherapy.
The problem is that so far, immunotherapy only works for some patients with certain types of cancer. Every cancer is different and the conditions that allow a good immune response to develop in a skin cancer are different to those needed to allow a good immune response to develop in a breast cancer. We know that cancers can put up barriers which help them resist immune attack – variations on these barriers exist in different cancers meaning that immunotherapies must be tailored to overcome the obstacles that a particular cancer type brings.
My laboratory is focussed on identifying and overcoming barriers to successful immunotherapy. Specifically, we are trying to understand how a population of immune cells, called regulatory T cells act to suppress anti-cancer immune responses and how they can be disabled to promote tumour immunity. In addition, we are examining tumour blood vessels and asking how we can manipulate these in order to allow immune cells better access to tumours in order that they can more efficiently find and kill their targets.
Addysgu
I deliver lectures and tutorials in Immunology to undergraduates in Medicine and Pharmacy.
SSC Tutorials and Lab Based Projects – Medical Students
European Society of Immunology Summer School in Sardinia 2009, 2011 and 2013, 2017.
John Humphreys Summer School, Havana, Cuba, 2012
External Examiner for BSc (HONS) in Immunology at Glasgow University 1.10.14 – 30.9.18
Bywgraffiad
I am a Professor at the Division of Infection and Immunity, Cardiff University. I gained a DPhil in 1995 in Professor Andrew McMichael's laboratory in Oxford, studying T cell responses to simian and human immunodeficiency viruses (SIV and HIV). With a Wellcome Trust travelling fellowship I subsequently moved to the laboratory of the Nobel laureate Professor Rolf Zinkernagel in Zurich to further study factors governing anti-viral immunity.
I then established my own laboratory with further Wellcome Trust funding at the Nuffield Department of Medicine in Oxford. At this time, the I started to investigate how lessons learnt from studying anti-viral immunity could be applied to cancer immunology. Specifically, my group focussed on regulatory T cells and were amongst the first to demonstrate that this T cell sub-population inhibited effective anti-cancer T cell responses. I moved to Cardiff in 2002, shortly afterwards gainin a senior fellowship from the MRC to expand the lab. The Cardiff lab, which currently receives its funding from Cancer Research UK, Cancer Research Wales, The Wellcome Trust and Breast Cancer Now takes basic research using animal models of cancer through to testing novel immunotherapies in patients.
Currently, I am the College of Life Sciences Cancer Theme Lead.
Anrhydeddau a dyfarniadau
Awards
1995 – 1998
Wellcome Trust Travelling Fellowship
University of Zurich, Switzerland.
1998 – 1999
Wellcome Trust Travelling Fellowship
University of Oxford.
2000 – 2005
Wellcome Trust Career Development Fellowship
University of Oxford / Cardiff University
2006 – 2011
MRC Non-Clinical Senior Fellowship
Cardiff University
2011 – 2016
Wellcome Trust University Award
Cardiff University
Aelodaethau proffesiynol
Treasurer of BSI Cancer Immunology Affinity Group.
Member of the British Society for Immunology (BSI) – National Cancer Research Institute, Cancer Immunology Steering Group
Safleoedd academaidd blaenorol
2013 - present: Professor, Cardiff University
2008 - 2013: Reader, Cardiff University
2002 - 2008: Lecturer / Senior Lecturer, Cardiff University
1999 - 2002: Career Development Fellow, Oxford University
1998 - 1999: Postdoctoral researcher, Oxford University
1995 - 1998: Postdoctoral researcher, University of Zurich
1991 - 1995: DPhil student, Oxford University
Pwyllgorau ac adolygu
Editorial Duties:
Review Editor Frontiers in Immunology since 2011
Associate Editor of Immunology since June, 2012
Member of Editorial Board Cancer Research 2013 – 2016
Grant Review / Board Memberships:
2016 - Member – Vice-chair - Chair of Cancer Research UK “Immunology Expert review Panel”
2017 – 2021 Member of Cancer Research UK Discovery Research Committee
2017 - 2023 Worldwide Cancer Research grant panel
2018 - Reviewer for the Cancer Research Center (CRC) Zürich (annual).
2018 - Reviewer for the Association of Italian Cancer Research (annual).
2019 – Invited Member of British Society for Immunology (BSI) – National Cancer Research Institute, Cancer Immunology Steering Group
2019 - 2022 Invited member of Canada Immunotherapy Network Research Management Committee (BioCanRx)
2020 Panel Member Cancer Research UK Quinquennial Review of Cancer Research UK Drug Discovery Units
Meysydd goruchwyliaeth
Recently Completed
Ana Pires Exploring the Reciprocal Relationship Between the Immune System and the Tumour Microenvironment
Stefan Milutinovic Exploring the Reciprocal Relationship Between the Immune System and the Tumour Microenvironment
Currently Supervising
Jake Scott Targeting the Vasculature to Improve cancer
Carissa Wong Addressing cellular interactions in tumours in vivo to control tumour immunity
Jessica Oliver Harnessing the Immune Response to Radiotherapy
Co-supervising
Valentina Bart An Objective Systems Approach to Dissect the Contribution of Macrophages to Cancer Growth and Metastasis
Lorenzo Capitani Targeting LAG3+ T Cells for Cancer Immunotherapy
Alicia Crespo Establishing a Potent and Highly Tumour Selective Immuno-Oncolytic Virotherapy for Colorectal Cancer
Rebecca Wallace Development of Precision Virotherapies Capable of evading Anti-vector Immunity
Eleanor Bird Investigating Links between Regulatory T Cell Depletion and Psychosis
Ymgysylltu
Gweithgareddau cyfredol
*Gweminarau Ymchwil Canser a fideos YouTube a gynhyrchwyd i drafod a rhannu datblygiadau ymchwil canser yn ystod pandemig COVID-19.
*Prosiect a ariennir gan ISSF Ymddiriedolaeth Wellcome Parhaus i ddatblygu gêm gyfrifiadurol i hyrwyddo dealltwriaeth o'r rhyngweithiadau rhwng canser a'r system imiwnedd.
Gweithgareddau yn y gorffennol
*Rhaglen ddogfen deledu o'r enw "Cancer Wars" a ddangoswyd ar BBC World
* Cymryd rhan yn rheolaidd yn Ysgol Feddygaeth Gwyddoniaeth ac Iechyd, Caerdydd.
* Cyfraniad i gylchlythyrau elusen canser (Tenovus, WCRF)
* Cyfweliad Radio BBC Cymru a chyfweliadau newyddion S4C.
* Ennill Cronfeydd Cymorth Strategol Sefydliadol Ymddiriedolaeth Wellcome (ISSF) ar gyfer prosiect a gynlluniwyd i ganiatáu i blant ysgol ddefnyddio eu gweledigaeth artistig i fynegi eu dealltwriaeth o wyddoniaeth biofeddygol, 2015/16. http://www.walesonline.co.uk/news/local-news/merthyr-tydfil-pupils-created-artwork-11000816 Facebook:
https://www.facebook.com/media/set/?set=a.246548445680853.1073741833.100819893587043&type=3
* Ennill gwobr "Sefydliad Ymchwil Prifysgol Imiwnedd Systemau" am brosiect a gynlluniwyd i gyflwyno'r cysyniad o ddata mawr i blant ysgolion cynradd ac archwilio cysylltiadau rhwng athroniaeth ac imiwnoleg. http://www.cardiff.ac.uk /news/view/384555-bridging-immunology-and-philosophy
*Cymryd rhan yn yr Eisteddfod gan gynnwys stondinau gwyddoniaeth a digwyddiadau siarad.
* Cynnal digwyddiadau rheolaidd i drafod ymchwil canser gyda chleifion, eu teuluoedd a'u ffrindiau (yn aml mewn partneriaeth ag elusennau canser.
* Noddodd Llefarydd Caerdydd CRUK gystadleuaeth "Young Art," Caerdydd. Mawrth 2019.
* Stondin Arddangos Celloedd Twyllodrus, Techniquest. Mawrth, 2019.
News articles
Contact Details
[email protected]
+44 29206 87012
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell Trydydd Llawr, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29206 87012
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell Trydydd Llawr, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
